Keymed Biosciences, Inc. (2162) AI Stock Analysis

• Market Cap: HK$12.51B
• Dividend Yield: N/A
• Average Volume (3M): 1.76M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.33
• Revenue Growth: 16.35%
• EPS Growth: -49.63%
• Country: HK
• Employees: 1,258
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -2.10
• Shares Outstanding: 279,735,570
• 10 Day Avg. Volume: 2,115,121
• 30 Day Avg. Volume: 1,762,177
• PEG Ratio: -0.65
• Price to Book (P/B): 4.15
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -22.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$60.00
• Price Target Upside: 25.52% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: ―

Keymed Biosciences, Inc. exhibits strong revenue growth and positive market momentum, which are significant strengths. However, the lack of profitability, negative cash flows, and high valuation risks weigh heavily on the overall stock score. The company's robust balance sheet provides some stability, but the path to profitability is crucial for future performance.

Keymed Biosciences, Inc. Business Overview & Revenue Model

Company Description

Keymed Biosciences Inc., a biotechnology company, engages in the research and development of biological therapies for the treatment of autoimmunity and oncology diseases. Its lead product candidate is CM310 for the treatment of moderate to severe atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic obstructive pulmonary disease (COPD). The company is also developing CM326, a monoclonal antibody targeting thymic stromal lymphopoietin to treat moderate-to severe AD, CRSwNP, asthma, and COPD. In addition, it develops CMG901 for the treatment of solid tumors, and gastric and gastroesophageal cancers; and CM313, a humanized monoclonal antibody to treat relapsed or refractory multiple myeloma, lymphoma and other hematological malignancies, and systemic lupus erythematosus. Further, the company is developing MIL95/CM312, a humanized monoclonal antibody targeting CD47; CM338, an antagonist antibody against mannose-binding lectinassociated serine protease-2; CM355 for the treatment of relapsed or refractory non-Hodgkin's lymphoma; CM336 to treat multiple myeloma; CM350 for the treatment of solid tumors; and CM369, an anti-CC chemokine receptor 8 monoclonal antibody. Keymed Biosciences Inc. was formerly known as 2Health Biosciences, Inc. The company was founded in 2016 and is headquartered in Chengdu, the People's Republic of China.

How the Company Makes Money

Keymed Biosciences, Inc. generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company's revenue streams include product sales upon receiving regulatory approval and successful market entry of its therapeutics. Additionally, Keymed may engage in strategic partnerships and collaborations with other pharmaceutical companies, which can result in milestone payments and royalties. The company also invests in research and development to expand its pipeline, aiming to increase future revenue potential as more products advance through clinical trials and reach the market.

Keymed Biosciences, Inc. Financial Statement Overview

Summary

Keymed Biosciences, Inc. is in a growth phase with increasing revenues. However, it faces challenges with profitability and positive cash flows. The company has a strong balance sheet with low leverage but negative cash flows and net losses raise concerns about financial sustainability. Investment in growth is evident, but profitability remains a concern.

Income Statement

Keymed Biosciences, Inc. has shown significant revenue growth from 2022 to 2024, with revenue increasing from 100 million to 428 million. However, the company is still operating at a loss, with a negative net profit margin and EBIT margin. The gross profit margin is high, indicating good product profitability, but this is offset by high operating expenses leading to negative net income.

Balance Sheet

The company maintains a strong equity position with a debt-to-equity ratio below 0.5, indicating low leverage. However, the ROE is negative due to consistent net losses. The equity ratio is healthy, suggesting a strong asset base compared to liabilities, which is crucial for future growth and stability.

Cash Flow

The free cash flow remains negative, reflecting high capital expenditures and operating losses. There is an absence of operating cash flow, highlighting challenges in converting revenue into cash. The company has not demonstrated positive cash flow to net income ratios, which are critical for long-term financial health.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
428.12M	354.10M	100.06M	110.27M	0.00
	Gross Profit
415.92M	317.22M	97.48M	93.07M	0.00
	EBIT
-618.10M	-434.80M	-295.38M	-3.88B	-804.70M
	EBITDA
-574.46M	-269.77M	-259.25M	-3.86B	-785.71M
	Net Income Common Stockholders
-515.24M	-359.36M	-308.12M	-3.90B	-832.73M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
2.16B	2.72B	3.18B	3.52B	354.08M
	Total Assets
3.77B	3.88B	3.93B	3.93B	529.95M
	Total Debt
753.24M	418.71M	121.97M	39.26M	66.86M
	Net Debt
334.82M	-432.32M	-482.10M	-1.48B	-132.54M
	Total Liabilities
1.29B	896.11M	593.10M	289.07M	1.62B
	Stockholders Equity
2.47B	2.99B	3.34B	3.65B	-1.09B
Cash Flow		Free Cash Flow
0.00	-686.23M	-681.48M	-387.50M	-139.26M
	Operating Cash Flow
0.00	-303.62M	-401.93M	-214.64M	-119.36M
	Investing Cash Flow
0.00	468.20M	-645.59M	-2.04B	-113.07M
	Financing Cash Flow
0.00	72.13M	-8.06M	3.64B	7.40M

Keymed Biosciences, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 47.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2162, the sentiment is Positive. The current price of 47.8 is above the 20-day moving average (MA) of 42.47, above the 50-day MA of 43.08, and above the 200-day MA of 38.16, indicating a bullish trend. The MACD of 1.29 indicates Negative momentum. The RSI at 68.34 is Neutral, neither overbought nor oversold. The STOCH value of 91.80 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2162.

Keymed Biosciences, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
2162	52 Neutral	HK$12.51B	―	-18.87%	―	16.35%	-49.63%
WXIBF		$12.78B	29.75	8.17%	―	―	―
1873	59 Neutral	HK$3.76B	21.09	4.47%	―	-9.75%	―
9995	51 Neutral	HK$33.02B	―	-56.68%	―	52.25%	11.46%
9926	50 Neutral	HK$73.83B	―	-8.98%	―	-54.66%	-123.11%
6185	48 Neutral	HK$10.61B	―	-4.41%	―	94.98%	85.69%

Keymed Biosciences, Inc. Corporate Events

Keymed Biosciences Announces 2025 Annual General Meeting and Key Resolutions

Keymed Biosciences Inc. has announced its upcoming Annual General Meeting scheduled for June 26, 2025, in Chengdu, China. The meeting will address several key resolutions, including the adoption of the 2024 financial statements, re-election of directors, and re-appointment of Ernst & Young as auditors. Additionally, the company seeks approval for the directors to issue new shares, which could impact its market position by potentially increasing capital for future projects.

Keymed Biosciences to Review Annual Results and Dividend

Keymed Biosciences Inc. has announced a board meeting scheduled for March 24, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024, and to consider the payment of a final dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.

Keymed Biosciences Gains Approval for Stapokibart in Allergic Rhinitis Treatment

Keymed Biosciences, Inc. announced that China’s National Medical Products Administration has approved the supplemental New Drug Application for Stapokibart, a humanized antibody, for the treatment of seasonal allergic rhinitis. This approval is based on a successful phase III study showing Stapokibart’s efficacy and safety in controlling nasal and ocular symptoms. This development marks Stapokibart as the first domestically manufactured IL-4R α antibody drug granted marketing approval, which could enhance Keymed’s positioning in the biopharmaceutical market.